North America Proton Therapy Market Size, Share, Growth, Trends and Industry Analysis: By Type of System (Single Room System and Multi-Room System), By Application (Paediatric Cancer, Head & Neck Cancer, Prostate Cancer, Lung Cancer, Gastro-Intestinal Cancer, Brain Cancer and Others), By End-User (Hospitals, Radiotherapy Centres and Others) and Country Forecast 2020-2031

North America Proton Therapy Market size was valued at US$ x million in 2024 and is expected to reach US$ x million by 2031, growing at a significant CAGR of 12.6% from 2025-2031. As protons have a positive charge, they can kill cancer cells at high energies. A non-invasive method of treating cancer, proton therapy uses radiation from protons. This kind of radiation treatment uses external beams to gently inject radiation from outside the body via the skin.

Proton therapy is the most common form of radiotherapy used for rhabdomyosarcoma, medulloblastoma, ependymoma, and Ewing sarcoma. Proton therapy, particularly pencil beam scanning, is expected to lower second cancer risks due to more targeted delivery of the radiation to the site of the first primary cancer. Globally and in the United States, cancer significantly influences society and drives the market growth of the market. The statistics on cancer depict the disease's impact on society over time.

For instance, according to the data updated by the American Cancer Society in January 2023, in the US, breast cancer is the most prevalent cancer to affect women. It represents one in three, or 30%, of all newly diagnosed female cancers in the nation each year. Over 75% of National Comprehensive Cancer Network centres provide the option of proton therapy for their patients or plan to incorporate proton therapy into their cancer programs which can be seen as an opportunity in North America's proton therapy market.

However, the lack of adequate healthcare infrastructure and high installation costs decline the market growth. For instance, due to a lack of proton therapy technology and devices, 64% of patients experienced an average wait time of more than 5 days for PT treatment authorization in 2022, an increase of 48% from 2021. In addition, 22% of patients in 2022 had an average wait time of more than 11 days, up from 14.7% in 2021. Proton therapy currently represents less than 1% of all radiation oncology treatments by modality, and approximately 70% of the U.S. population lives more than 100 miles from a treatment centre.